New study reveals weight-loss drugs help during treatment but weight returns rapidly after stopping. Here's what they found.

Novo Nordisk announced it is cutting ties with telehealth giant Hims & Hers Health, pulling its blockbuster drug Wegovy from the platform after accusing the company of selling “illegitimate, knockoff ...

Patients put on weight loss drugs like Ozempic and Wegovy may start regaining weight within weeks of discontinuing them, a ...

If you’ve been taking Ozempic or Wegovy (both of which contain the active ingredient semaglutide), you might wonder, How long ...

GLP-1 drugs like semaglutide (Ozempic) and tirzepatide (Mounjaro) may shrink fat, but also crucial muscle mass, with little ...

Ozempic is an FDA-approved medication for people who have type 2 diabetes. It’s often prescribed “off-label” for weight loss ...

Demand for glucagon-like peptide-1 weight-loss drugs — such as Ozempic, Zepbound and Wegovy — coupled with limited insurance ...

CVS Caremark will stop covering Eli Lilly’s Zepbound. Wegovy, the GLP-1 medication to treat obesity from Lilly competitor Novo Nordisk, will still be covered under plans managed by CVS Caremark.

The amount of weight loss seen in the trial, 9.4%, was less than in other studies of Wegovy, which showed average weight loss closer to 15%. ... Wegovy costs $1,349 a month before insurance.

Newly released clinical trial data on the GLP-1 agonist drug Wegovy found that weight loss was sustained for up to four years after participants started taking the once-weekly injected medication.

San Francisco telehealth company Hims & Hers saw its stock plunge more than 30% earlier this week after a partnership with ...